The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Aciclovir 200mg/5ml Oral Suspension

Syri Pharma Limited t/a Thame LaboratoriesPA22697/001/001

Main Information

Trade NameAciclovir 200mg/5ml Oral Suspension
Active SubstancesAciclovir
Dosage FormOral suspension
Licence HolderSyri Pharma Limited t/a Thame Laboratories
Licence NumberPA22697/001/001

Group Information

ATC CodeJ05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AB01 aciclovir


License statusAuthorised
Licence Issued26/05/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportPDF Version
« Back